In a stride for Ayurvedic medicine, Baba Ramdev-owned Patanjali Ayurved's research on vitiligo treatment has earned global recognition, with their herbo-mineral formulation, Melanogrit, featured on Bioscience Reports, a prestigious international journal under the umbrella of the Biochemical Society, UK.
According to a statement by Patanjali Ayurved, the study focuses on Melanogrit's therapeutic potential, specifically its ability to potentiate melanin production in B16F10 cells, responsible for the melanogenesis process. The study, said the statement, found that Melanogrit boosts cell tyrosinase activity and MITF levels while blocking pERK, thus encouraging melanin production.This breakthrough has profound implications for treating conditions like vitiligo, characterized by white patches on the skin due to disruptions in melanocyte function.
Baba Ramdev File
Acharya Balkrishna of Patanjali Yogpeeth expressed immense pride in this milestone, emphasising the intensive research conducted by scientists at the Patanjali Research Foundation on skin white patches, utilizing the principles of Ayurveda.
Balkrishna highlighted that Melanogrit effectively enhanced the expression of crucial melanogenesis pathway genes such as MITF, TYR, and TRP1, leading to an observable rise in cellular tyrosine activity. Furthermore, it demonstrated the ability to ameliorate the translational levels of MITF by inhibiting pERK.
Patanjali, known for its research in Ayurveda, has been treating thousands of patients suffering from vitiligo and leucoderma for years. Thus, international recognition of Melanogrit's cellular validation by the UK and the global scientific community marks a significant achievement, said the company.
India, once a prominent force in traditional and alternative medications and therapy, is poised to maintain its leadership in the global community. Patanjali's breakthrough with Melanogrit not only signifies a leap forward in Ayurvedic research but also serves as a celebration of India's rich scientific heritage, setting the stage for continued contributions to the world of medicine, the company statement said.
